Cathelicidin-WA Facilitated Intestinal Fatty Acid Absorption Through Enhancing PPAR-γ Dependent Barrier Function

Xin Zong†, Xiaoxuan Cao†, Hong Wang, Xiao Xiao, Yizhen Wang* and Zeqing Lu*

Key Laboratory of Animal Nutrition and Feed Science in Eastern China, Ministry of Agriculture, College of Animal Sciences, Zhejiang University, Hangzhou, China

The molecular mechanisms underlying the cellular uptake of long-chain fatty acids and the regulation of this process have been debated in recent decades. Here, we established an intestinal barrier dysfunction model in mice and Caco2 cell line by Lipopolysaccharide (LPS), and evaluated the fatty acid uptake capacity of the intestine. We found that LPS stimulation restricted the absorption of long chain fatty acid (LCFA), while Cathelicidin-WA (CWA) pretreatment facilitated this physiological process. At the molecular level, our results demonstrated that the stimulatory effects of CWA on intestinal lipid absorption were dependent on cluster determinant 36 and fatty acid transport protein 4, but not fatty acid–binding protein. Further, an enhanced intestinal barrier was observed in vivo and in vitro when CWA alleviated the fatty acid absorption disorder induced by LPS stimulation. Mechanistically, peroxisome proliferator-activated receptor (PPAR-γ) signaling was considered as a key pathway for CWA to enhance LCFA absorption and barrier function. Treatment with a PPAR-γ inhibitor led to impaired intestinal barrier function and suppressed LCFA uptake. Moreover, once PPAR-γ signaling was blocked, CWA pretreatment could not maintain the stability of the intestinal epithelial cell barrier or LCFA uptake after LPS stimulation. Collectively, these findings suggested that PPAR-γ may serve as a target for specific therapies aimed at alleviating fatty acid uptake disorder, and CWA showed considerable potential as a new PPAR-γ agonist to strengthen intestinal barrier function against fatty acid malabsorption.

Keywords: cathelicidin-WA, fatty acids, intestinal barrier, PPAR-γ, lipopolysaccharides

INTRODUCTION

Long-chain fatty acids (LCFAs, FAs with 12–18 carbons and varying degrees of unsaturation), stored as triglycerides in the body, serve several important functions in the human body (1). First, LCFAs are one of the most important sources of energy, and could provide twice as much energy as carbohydrates and proteins on a per weight basis (2). Second, dietary LCFAs are the only source of essential fatty acids that serve as substrates for lipid biosynthesis, and protein modification (1). Intestinal fatty acid absorption is a multistep process, that is associated with fatty acid transporters on the apical membrane of enterocytes, including cluster determinant 36 (CD36), plasma membrane–associated fatty acid–binding proteins (FABP), and a family of fatty acid
transport proteins (FATP) 1–6 (3–5). Because of the metabolic syndrome is related to cardiovascular disease, obesity, diabetes, and cancer, many studies have focused mainly on identifying cellular, physical/chemical, and genetic determinants of intestinal fatty acid absorption in humans and laboratory animals (6).

It is generally known that before cholesterol and fatty acid molecules can interact with their corresponding transporters for uptake and absorption, they must pass through a diffusion barrier (7, 8). Intestinal mucosa is a diffusion-limiting barrier, that simultaneously promotes nutrient and water transport while serving as a protective barrier, and neither property is absolute (9). Wang et al. (7) found that epithelial mucin1 was necessary for normal intestinal uptake and absorption of cholesterol in mice, as evidenced by a 50% reduction in cholesterol absorption efficiency in mucin1 knockout mice.

Cathelicidin peptides, a family of antimicrobial peptides, not only exhibit antimicrobial activities (10), but also function as immune regulators (11). Recently, cathelicidin peptides have been found to protect intestinal epithelial barrier function in infected mice (12, 13). Our previous study showed that cathelicidin peptide (CWA) from snake attenuated EHEC-induced inflammation and microbiota disruption in the intestine of mice (14). Nevertheless, the effects of CWA on fatty acid absorption and the underlying mechanisms remain unknown.

In this study, we characterized the effect of cathelicidin peptide CWA on intestinal LCFA absorption during Lipopolysaccharide (LPS) induced intestinal barrier dysfunction in mice and Caco-2 cells. We present new evidence implicating CWA as a potent stimulator of LCFA absorption in the intestine and explore potential mechanisms through enhancing peroxisome proliferator activated receptor (PPAR) γ-dependent barrier function.

MATERIALS AND METHODS

Peptide Synthesis

Cathelicidin-WA (CWA) was chemically synthesized by a standard solid-phase method using Automatic Peptide Synthesizer (Aapptec, Louisville, KY, USA) from C-terminus to N-terminus according to the sequence designed by our laboratory (14). The synthetic CWA was purified by semi-preparative HPLC, achieving 96% purity of the peptide and characterized by analytical HPLC (Agilent 121 Technologies, CA, USA). The peptide was dissolved in PBS and stored at −80°C until use.

Reagents

Ultrapure LPS from E.coli strain O55:B5, FD4 and 4,4-difluoro-5,7-dimethyl-4-bora-3a, and 4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY-C16) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Olive oil and palmitic acid were purchased from Aladdin (Shanghai, China). Tyloxapol was purchased from Sigma Aldrich (St. Louis, USA). GW9662 and Rosiglitazone were obtained from Target Molecule (Shanghai, China). The rabbit antibodies for β-actin, ZO-1, CD36, FATP4, I-FABP, PPAR-γ were purchased from Proteintech (Wuhan, China). The rabbit antibodies for occludin and claudin-1 were obtained from Abcam (Cambridge, MA, USA). The secondary antibody (goat-anti-rabbit IgG) was purchased from HuaAn (Hangzhou, China).

Animals and Treatments

Forty C57BL/6 male mice (5–6 weeks of age) were obtained from the Laboratory Animal Center of Zhejiang University. All the mice were housed in plastic cages on a layer of wood shavings with chow diet and water ad libitum under standard conditions. The animals were allowed to acclimatize to the environment for 1 week before the experiment. The animal experimental protocol was approved by the Animal Care and Use Committee of Zhejiang University.

As shown in Table 1, the mice were randomly divided into four groups of 10 each: control, LPS treatment (10 mg/kg), CWA pretreatment (5 mg/kg), and CWA+LPS (5 mg/kg CWA pretreatment followed by 10 mg/kg LPS treatment). CWA was injected intraperitoneally once daily for 6 days, whereas the control and LPS groups were intraperitoneally injected with an

| TABLE 1 | Experimental design and scheme of the animal treatments. |
| --- | --- | --- |
| Control | PBS 200 µL/d | PBS 200 µL |
| LPS | PBS 200 µL/d | LPS 10 mg/kg |
| CWA+LPS | CWA 0.6 mg/kg/d | LPS 10 mg/kg |
| CWA | CWA 0.6 mg/kg/d | PBS 200 µL |
| 6 d | 6 h | 30min Tyloxapol |
| 90min | Samples collected |

200 µL olive oil (containing 30 mg/mL palmitic acid)
equal volume of sterile saline. On day 6, mice in the LPS and CWA+LPS groups were intraperitoneally injected with LPS (10 mg/kg, 200 µL per mouse) 1 h after CWA or saline treatment, and the other groups were injected with an equal volume of saline. The lipid absorption assessment was performed 6 h after LPS or saline injection, and the mice were administered 200 µg/kg, 200 mg/kg, 200 mg/kg, and 200 mg/kg LPS groups were intraperitoneally injected with LPS (10 mg/kg, 200 µL per mouse) 1 h after CWA or saline treatment, and the other groups were injected with an equal volume of saline. The lipid absorption assessment was performed 6 h after LPS or saline injection, and the mice were administered 200 µL olive oil (containing 30 mg/mL palmitic acid) by gavage and then received an intraperitoneal injection of tyloxapol (15% in saline, 0.5 g/kg) 30 min later. The mice were killed and blood samples were collected by cardiac puncture 2 h after an oral fat bolus.

**Cell Culture**

The human colorectal cancer cell line Caco-2 cells (a generous gift from Dr. Fengjie, College of Animal Science, Zhejiang University) were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM-F12 medium supplemented with 10% (V/V) fetal bovine serum and antibiotics (100 U/ml penicillin and 100 µg/mL streptomycin sulfate) at 37°C in humidified incubator under 5% CO2 in air.

**Intestinal Morphology**

The proximal jejunum of the mice was fixed in 4% paraformaldehyde and embedded by paraffin, followed by slicing and staining with hematoxylin and eosin (H&E) or oil red O staining solution. Images of the slices were obtained using the Leica DM3000 Microsystem, then the villi height and crypt depth were measured by Leica Application Suite Version 3.7.0 (Leica, Wetzlar, Germany).

**Transmission Electron Microscopy**

The tight junction structure was observed by TEM as previously described (10). A jejunum specimen of ~1 cm in length was excised with a sharp scalpel and fixed in 2.5% glutaraldehyde for 4 h at 4°C, followed by fixation in osmic acid and embedding in epon. Ultrathin sections were obtained using a diamond knife and stained with uranyl acetate and lead citrate before examination by TEM (JEM-1011; JEOL USA). Digital electron micrographs were acquired with a 1,024 × 1,024 pixel CCD camera system (AMT Corp., Denver, MA).

**Serum Lipids and Inflammatory Cytokines**

To determine the concentration of TNF-α and IL-6 in the serum, ELISA kits (Raybiotech, Guangzhou, China) were used. The assays were carried out according to the manufacturer's instructions.

**Determination of Fatty Acid Uptake in vitro**

Caco2 cells were seeded in BIOCOAT Collagen I 96-well plates (black wells, clear bottom) for 1 week because of the differentiation process. The fatty acid uptake was evaluated by intracellular BODIPY-labeled fatty acid as previously described (15). Briefly, the cells starved for 1 h in MEM medium (without phenol red), which was and replaced with 100 µL of a BODIPY-C16 reaction mixture prepared in D-Hanks (5 µM CI-BODIPY-C16, 5 µM fatty-free BSA and 3.9 mM trypan blue, 50 µL MEM medium). The plates were maintained in the dark and incubated for 10 min at 37°C in 5% CO2. Then the intracellular fluorescence was measured by a Molecular Devices SpectraMax M5 plate reader following excitation at 485 nm and emission at 528 nm. Fatty acid uptake differences were compared by the relative fluorescence.

**Measurement of Transepithelial Electrical Resistance (TEER)**

Caco-2 cells were grown on 12-mm Transwell filters (Corning, NY, USA). When the TEER of cell monolayers became stable (~3 weeks later), they are ready to be studied. Then the TEER of polarized Caco-2 cells were measured using Millicell-ERS voltohmmeter (Millipore, USA) at 1, 3, 6, 12 h after LPS stimulation. Changes were calculated as a percentage of baseline TEER (0 h).

**In vitro Intestinal Paracellular Permeability Assay**

Immediately after the last determination of TEER value, 100 µL of 4 kDa fluorescein isothiocyanate-labeled dextran (FD4, 1 mg/mL) was added to apical chamber. The transwell plates were cultured at 37°C for 30 min, and then the concentrations of FD4 in the basolateral chamber were determined at an excitation wavelength of 480 nm and an emission wavelength of 520 nm according to the standard curve, which was established from the fluorescence of FD4 at concentration of 100, 200, 500, 1,000, 2,000, 3,000, 4,000, 5,000 pmol/L.

**TABLE 2 | Primer sequences for q-PCR.**

| Gene     | Sequence (5′ → 3′)     | Genebank No. |
|----------|------------------------|--------------|
| IL-6     | Forward: TCCTACCCCAATTTCCTAGCT | NM_031168.2  |
|  | Reverse: TGCTTCCTGTCTCTAGCCAC |             |
| TNF-α    | Forward: GCTTTGTCTGACGACTCTGCG   | NM_013693.3  |
|  | Reverse: GATCTGGAGTGTGGTGGTGGG   |             |
| Occludin | Forward: CAGGCTGATGGTCAACGAG   | NM_008756.2  |
|  | Reverse: CAGGGCTACGAAATGACGAA   |             |
| ZO-1     | Forward: GGAAAGATTCAGCTGGCAAG   | NM_009386.2  |
|  | Reverse: AGTGGAGAAGACCTGCGGAG   |             |
| Claudin-1| Forward: GGCCTTGACCTGACTTTACC  | NM_016674.4  |
|  | Reverse: GAGACACCTATGCCGGTTT    |             |
| ApoA-IV  | Forward: GCCTGCAAGGAGAAACTCAAC | NM_007468.2  |
|  | Reverse: GCTGTCGCTATTTTGCGGAG  |             |
| CD36     | Forward: GGCACCCAACCAAATAGCA    | NM_007643.4  |
|  | Reverse: AAGGCGTAGAAACCATCACCC  |             |
| FATP4    | Forward: GACTTTCGACGGCTTTCCA   | NM_011998.5  |
|  | Reverse: AGGACAGGATGCGGCTATTG  |             |
| I-FABP   | Forward: ATGCCCACTAGCTGTTGTA  | NM_007980.3  |
|  | Reverse: AACCTAACCAGCTTACAGC    |             |
| DGAT-1   | Forward: TTTCGCTTGAGGCTTGTAGT  | NM_010046.3  |
|  | Reverse: ATCTTGCAAGCAGTCGACC   |             |
| DGAT-2   | Forward: GGGCACTGGTTGCTGTAACT  | NM_026384.3  |
|  | Reverse: TTCTCGGAGTGACCGTCTC   |             |
| β-actin  | Forward: TGAGCTCGCCTACCCCT     | NM_007393.5  |
|  | Reverse: GCCCTCAGCCTGCCGTTT    |             |
RNA Extraction and Quantitative Real Time PCR (q-PCR)

Total RNA was isolated using TRIzol reagent (Invitrogen, USA). The concentration and purity of the RNA were evaluated using NanoDrop2000 (Thermo Fisher Scientific, Waltham, USA). Then 2 µg RNA was subjected to reverse transcription reaction with random primers. q-PCR was performed with SYBR Green master mix (Roche, Mannheim, Germany) using a StepOnePlus Real Time PCR systems (Applied Biosystems, Foster City, USA). The gene-specific primers for the q-PCR are listed in Table 2 and the relative mRNA expression of the target gene was determined using the 2-ΔΔCt method.

Western Blot Analysis

Total protein extracts of scraped jejunal mucosa or cells were harvested by Total Protein Extraction Kit (KeyGen BioTECH, Nanjing, China). Equivalent amounts of protein were separated by SDS-PAGE and electroblotted onto PVDF membranes (Millipore, Bedford, MA, USA) followed by blocking with 5% fat-free milk. Then membranes were incubated overnight at 4°C with primary antibodies including ZO-1, occludin, claudin-1, CD36, FATP4, I-FABP, PPARγ, and β-actin. After washing with TBST, membranes were incubated with secondary antibodies for 1 h at room temperature. The protein bands were visualized with an ECL assay kit (Servicebio, Wuhan, China).
Statistical Analysis
All statistical calculations were performed in GraphPad Prism 7 (San Diego, USA) and expressed as the mean ± SD. Data were subjected to one-way ANOVA with Duncan’s multiple range test. *P < 0.05 was considered as statistically significant.

RESULTS
CWA Prevented the LCFA Absorption Disorder in LPS-Treated Mice
To directly examine whether CWA facilitates the utilization of LCFA, we measured intracellular triglyceride levels in the intestine of mice that received palmitic acid orally. As shown in the oil red O staining results (Figure 1A), some vacuolized enterocytes on the remaining villus tops in mice treated with LPS only contained a few fat droplets, while fat droplets were completely absent in the villus interstitium, which was significantly different from the control group. In contrast, in CWA-pretreated mice, most enterocytes contained no fat droplets while many small fat droplets were present in the villus interstitium. As an independent validation, a similar phenomenon was found by TEM observation (Figure 1B).

To substantiate this finding further, we found that the level of palmitic acid was not different in LPS-treated mice with or without CWA stimulation, but it increased significantly in CWA only-treated mice compared to control mice (Figure 1C). Although the levels of serum cholesterol were not changed between treatments, the level of triglycerides, the main storage form of fatty acids, in LPS-treated mice decreased markedly in comparison with control mice, and CWA pretreatment effectively alleviated the symptoms (Figures 1D,E). Moreover, we analyzed glucose and lipid metabolites in the serum. As shown in Figures 1F,G, compared with the control group, LPS stimulation decreased high-density lipoproteins (HDL) and low-density lipoproteins (LDL) levels, and CWA treatment prevented this decrease. However, it was likely that glucose metabolism was not sensitive to LPS and CWA stimulation (Figure 1H). These results indicated that LPS restricted LCFA absorption in the intestine, while CWA pretreatment restored the absorptive process during LPS stimulation.

CWA Enhanced the Expression of Fatty Acid Absorption-Related Genes in LPS-Treated Mice
To investigate the genetic basis of the effect of CWA on the absorption of LCFA, the expression of specific protein transporters implicated in intestinal fatty acid absorption was examined by q-PCR. We found that the expression of CD36 and FATP4 decreased markedly after LPS stimulation, while CWA pretreatment blocked the decrease in their expression induced by LPS (Figures 2A,B). Conversely,
Effects of CWA on LPS-Induced Mouse Intestinal Barrier Injury

Cathelicidin peptides improve the intestinal barrier function. We investigated whether the improved fatty acid absorption by CWA was related to its role in regulating intestinal barrier function. As shown in Figure 3A, compared with the control mice, increased villous height and decreased crypt depth were observed in the jejunum after LPS challenge, whereas CWA pretreatment attenuated the LPS-induced villous atrophy and crypt hyperplasia.

Tight junction proteins (TJs) exert a primary role in maintaining intestinal barrier function (9). To further evaluate the protective effect of CWA on the barrier function, transmission electron microscopy was used to observe TJ structure. We found that LPS destroyed the TJ structure in the jejunum, which was clearly prevented by CWA pretreatment.

and interestingly, compared with the control group, the expression of intestinal fatty acid binding protein (I-FABP) increased notably with LPS treatment, but no difference was noted in CWA-pretreated mice (Figure 2C). However, the expression of intestinal ApoA-IV, DGAT1, and DGAT2 upon LPS stimulation did not change among any of the treatment groups (Figures 2D–F).

Furthermore, Western blot analyses showed that exogenous CWA increased CD36 and FATP4 protein levels in mice treated with LPS, which was consistent with the qPCR results (Figure 2G). Curiously, there was no difference in the IFABP protein levels between each treatment (Figure 2G). These experiments demonstrated that the stimulatory effects of CWA on intestinal lipid absorption were dependent on the fatty acid transporters CD36 and FATP4.
FIGURE 4 | CWA (20 µg/ml) accelerated absorption of Bodipy FA in LPS injured Caco-2 cell. (A) Effect of CWA on cellular permeability to FD4. (B) Effect of CWA on TEER of a Caco-2 cell monolayer. (C) Western blot analysis of tight junction proteins in Caco-2 cell. (D,E) Effect of CWA on fatty acids uptake in Caco-2 cell. Caco-2 cells treated with medium in the presence of the Bodipy-C16 (8 µM) for 5 min. (D) The absorption level of Bodipy C16 was observed by confocal microscope. (E) General level of Bodipy FA absorption was measured by Microplate reader. The data are expressed as the mean ± SEM, n = 3, biological replicates; bars with different small capital letters are statistically different from one another.

(Figure 3B). Moreover, the expression of TJ markers, zonula occludens (ZO)—1, occludin, and Claudin-1 were detected by qPCR. All genes were downregulated in mice treated with LPS alone compared with normal animals. Administration of CWA increased the expression of all genes bringing it close to the level of the control group (Figures 3C–E). Additionally, we found that CWA attenuated the inflammatory response caused by LPS stimulation. Compared with the control group, the LPS-treated mice exhibited highly elevated expression of TNF-α and IL-6. The administration of CWA to LPS-treated mice significantly decreased these inflammatory mediators (Figures 3F–I). These results further strengthen the evidence linking CWA and intestinal barrier injury.

CWA Prevented LCFA Malabsorption in LPS-Injured Caco-2 Cells

To understand the mechanism by which CWA promoted LCFA absorption, a barrier-injured intestinal epithelial cell model was established with Caco-2 cells cultured in Transwell plates. Consistent with the in vivo findings, the results in Figure 4A show only a 20% drop in TEER values compared to the baseline values under LPS treatment conditions in the cells pretreated with CWA, whereas an ~40% decline was found in the cells treated with LPS alone (Figure 4B). The effect of CWA was further confirmed with a FD4 permeability assay (Figure 4A). At the molecular level, we verified that CWA pretreatment prevented the decreased expression of TJ markers ZO-1, occludin, and Claudin-1 induced by LPS challenge (Figure 4C). These results illustrated the protective effects of CWA on LPS-induced intestinal barrier dysfunction in vitro.

4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (Bodipy-C16) is a fatty acid analog used to study fatty acid uptake in cells (16). The incorporation of this analog into cellular lipids is similar to that of native LCFA. We used the fluorescent fatty acid analog Bodipy-C16 to measure the ability of the Caco-2 cells to take up fatty acids. Notably, upon LPS stimulation, LCFA uptake was limited, while CWA pretreatment dramatically increased the amount of fatty acid uptake when compared to the LPS-challenged group (Figure 4D). Similarly, the promotion of fatty acid uptake by
CWA in cells treated with LPS was further confirmed by confocal microscopy with Bodipy-C16 (Figure 4E).

**CWA Strengthened LCFA Absorption Dependent on FATP4 and CD36**

In humans and mice, CD36 is detected in epithelial cells of the small intestine along the gastrocolic and crypt-to-villus axes in a pattern paralleling that of other proteins implicated in LCFA uptake (5, 17). First, the expression of specific protein transporters implicated in intestinal fatty acid absorption was examined by Western blot analyses. Consistent with previous findings, no difference was noted in the protein levels of IFABP (Figure 5A). Moreover, we found that CWA significantly increased the expression of CD36 and FATP4, whose expression was suppressed by LPS stimulation (Figure 5A).

Immunofluorescence visualization of CD36 suggested that this protein is expressed on the membrane, poised for fatty acid uptake (Figure 5B). LPS stimulation visibly decreased the expression of CD36, which was prevented by CWA pretreatment (Figure 5B). Thus, a potential mechanism by which CWA promotes LCFA absorption is through increasing the expression of CD36 on the membrane by means of enhanced barrier function.

**CWA Facilitated LCFA Absorption and Barrier Function Through PPAR-γ Activation**

PPAR-γ signaling is required for both intestinal barrier function and nutrient transport (18, 19). We hypothesized that CWA enhanced barrier function and that LCFA absorption was dependent on PPAR-γ. We first analyzed the expression of PPAR-γ, and as shown in Figure 6A, CWA treatment activated PPAR-γ in the presence or absence of LPS stimulation. To test the hypothesis further, an inhibitor and agonist of PPAR-γ were used. As expected, the inhibitor GW9662 inhibited and the agonist rosiglitazone activated the expression of PPAR-γ (Figure 6B). Furthermore, we found that CWA pretreatment failed to maintain the stability of the intestinal epithelial cell
FIGURE 6 | CWA facilitated intestinal fatty acid absorption and barrier function through PPAR-γ activation. (A) Effect of CWA on PPAR-γ activation. (B) Effects of GW9662 and Rosiglitazone on PPAR-γ. The top panel shows the relative levels quantified by densitometry and normalized to β-actin. (C) PPAR-γ is essential to the protection effects of CWA on FD4 permeation. (D) PPAR-γ activation ameliorates the LPS-induced TEER decrease. (E) PPAR-γ activation enhances intestinal fatty acid absorption. (F) CWA facilitated intestinal fatty acid absorption dependent on PPAR-γ activation. Fatty acid uptake was assessed by intracellular fluorescence intensity of Bodipy-C16. (G) CWA enhanced intestinal fatty acid absorption through activating PPAR-γ. Fatty acid uptake was assessed through intracellular (Continued)
barrier after LPS administration when PPAR-γ signaling was inhibited (Figure 6C). Comparisons showed that the effect of CWA was similar to that of rosiglitazone (Figure 6C). These results indicated that CWA was a potential agonist of PPAR-γ. Moreover, the effect of rosiglitazone on TEER was in line with the effect of CWA, which further confirmed the conclusion that PPAR-γ is a key factor in the effect of CWA on the intestinal barrier (Figure 6D).

We further investigated the role of PPAR-γ in the process of fatty acid uptake, which is closely related to barrier function. Based on the result of fatty acid uptake ability, we found that PPAR-γ activation resulted in enhanced fatty acid uptake, regardless of LPS stimulation (Figure 6E). These findings were validated with the PPAR-γ inhibitor (Figure 6F). Next, we assessed the effects of CWA on fatty acid uptake upon LPS challenge when the expression of PPAR-γ was suppressed. As shown in Figure 6F, once the activity of PPAR-γ was inhibited, CWA was not able to maintain the absorption of fatty acids in the cells treated with LPS. In addition, the above conclusions were ascertained visually (Figure 6G). At the gene level, consistent with our hypothesis, when the activity of PPAR-γ was inhibited, the expression of FATP4 and CD36 were suppressed. Moreover, the opposite effect was observed with PPAR-γ agonists, which further verified the result (Figure 6H).

**DISCUSSION**

In our work, sufficient evidence has demonstrated that, in addition to its protective effects on the intestinal barrier, exogenous CWA may act as a PPAR-γ agonist controlling intestinal LCFA absorption. More concretely, we established LPS-induced intestinal barrier dysfunction models in mice and the Caco2 cell line and evaluated the fatty acid uptake capacity of the intestine, which still requires further investigation. Then, we discovered that CWA, a cathelicidin peptide identified in snakes, enhanced LCFA uptake, especially under the pathological state of the intestine. Finally, the molecular mechanism was elucidated, showing that CWA facilitated intestinal fatty acid absorption by enhancing PPAR-γ-dependent barrier function.

LCFAs are well-recognized as fundamental and essential nutrients for human physiology. Most LCFAs are present as esters in phospholipids and triglycerides, forms in which they perform the vital functions of membrane maintenance and energy storage. Our data suggested that CWA enhanced intestinal LCFA uptake in vivo and in vitro, which was further confirmed by the cellular triglycerides. However, CWA had no effect on the glucose balance. These results indicated that there were different absorption mechanisms between fatty acids and glucose, which was dependent on glucose transporters, such as GLUT family (20). There is debate about the overall fatty acid uptake process and whether one or more membrane-associated proteins could regulate cellular fatty acid uptake (21–23). The theory that transfer to the cytosolic leaflet of the membrane is carried out by a membrane-bound protein is the proposed pathway for the movement of LCFA into cells through the plasma membrane (24, 25). Numerous proteins have been identified for the movement of LCFA across the membrane, such as CD36, FATP, FABP, and caveolin-1 (26–28). Our data suggested that CD36 and FATP4, but not IFABP, were involved in the process of CWA regulating LCFA uptake. To our surprise, unlike the protein level, LPS stimulation significantly increased the mRNA level of IFABP. We speculated that CWA may be involved in the translation of IFABP, which still needs further study. Diacylglycerol O-acyltransferase (DGAT1) 1/2, the key enzymes in triglyceride synthesis (29), were not sensitive to CWA or LPS stimulation. The results indicated that the beneficial effects of CWA were limited to LCFA uptake.

A poorly understood feature of metabolic syndrome is that it is associated with intestinal barrier dysfunction (8, 30). The intestinal barrier is mainly composed of the mucus layer, the epithelial layer, and the underlying lamina propria. Tight junction (TJ) proteins are apical intercellular structures that connect the intestinal epithelial cells and regulate paracellular permeability (31, 32). The core TJ complex, consists of occludin, ZOs, and members of the claudin family. TJ plays a critical role in paracellular permeability by conferring selectivity to the flow of ions, small molecules and solutes between cells, which is important for the responsiveness of cells to directional stimuli and transport functions (33). Therefore, we hypothesized that CWA enhanced fatty acid absorption by strengthening barrier function. As expected, from the results of H&E, TJ structure, and the expression of a TJ marker, we found that CWA effectively attenuated LPS-induced intestinal barrier dysfunction in the jejunum. Furthermore, the results were confirmed in polarized Caco-2 cells cultured in Transwell in vitro. Consistent with this finding, previous studies have shown that the cathelicidin peptide cathelicidin-BF attenuates the DSS-induced disruption of mucus expression in the mouse intestine (34). Moreover, LL-37 can enhance epithelial barrier function by regulating Rac1 activation (35). This evidence indicated that the promotion of LCFA uptake by CWA was closely related to its barrier regulation function. However, the direct interaction needs to be further identified by TJ marker gene knockdown.

PPAR-γ is a member of the nuclear hormone receptor superfamily and a ligand-activated transcription factor (36, 37). It plays a critical role in the control of not only adipocyte differentiation, lipid metabolism and immunity but also the barrier functions of epithelial and endothelial cells (37–40). In the present study, in addition to CWA treatment enhancing the
expression of PPAR-γ, similar effects on LCFA uptake and barrier function were also found in cells treated with CWA and the PPAR-γ agonist rosiglitazone. These results suggested that CWA may be a potential agonist of PPAR-γ. More interestingly, once PPAR-γ signaling was inhibited, CWA pretreatment could no longer maintain LCFA uptake and the barrier function after LPS stimulation. Therefore, PPAR-γ was indispensable for CWA to regulate LCFA uptake through enhancing barrier function. Taken together, our results demonstrate that exogenous CWA may thus provide a possible strategy for fatty acid absorption disorder in pathologic conditions.

DATA AVAILABILITY
The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT
The animal study was reviewed and approved by Animal Care and Use Committee of Zhejiang University. Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS
XZ, XC, and YW designed the research. XC and HW performed experiments and collected data. XC analyzed the data. XZ wrote the manuscript. XX, YW, and ZL reviewed the manuscript.

FUNDING
This work was supported by the National Natural Science Foundation of China (Grants 31630075, 31601947).

ACKNOWLEDGMENTS
The authors thank the Electronic Microscopy Center and Agricultural, Biological, and Environmental Test Center of Zhejiang University for assistance with confocal microscopy and TEM studies.

REFERENCES
1. Makrides M, Collins CT, Gibson RA. Impact of fatty acid status on growth and neurobehavioural development in humans. *Matern Child Nutr.* (2011) 7 (Suppl. 2):80–8. doi: 10.1111/j.1740-8709.2011.00304.x
2. Wang DQ. Regulation of intestinal cholesterol absorption. *Annu Rev Physiol.* (2007) 69:221–48. doi: 10.1146/annurev.physiol.69.031905.160725
3. Abumrad N, Harmon C, Ibrahimai A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. *J Lipid Res.* (1998) 39:2309–18.
4. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, et al. Identification of the major intestinal fatty acid transport protein. *Mol Cell.* (1999) 4:299–308. doi: 10.1016/S1097-2765(00)00332-9
5. Poirier H, Degrange P, Niot I, Bernard A, Besnard P. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP). *Eur J Biochem.* (1996) 238:68–73. doi: 10.1111/j.1432-1033.1996.tb368.x
6. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular mechanism of intestinal fatty acid absorption. *Eur J Clin Invest.* (2013) 43:1203–23. doi: 10.1111/eci.12161
7. Wang HH, Aldhal NH, Gendler SJ, Wang DQ. Lack of the intestinal Muc1 mucin impairs cholesterol absorption but not fatty acid uptake in Muc1–/– mice. *Am J Physiol Gastrointest Liver Physiol.* (2004) 287:G547–54. doi: 10.1152/ajpgi.0097.2004
8. Thaisse CA, Levy M, Grosova I, Zheng D, Soffer E, Blacher E, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science.* (2018) 359:1376–83. doi: 10.1126/science.aar3318
9. Odnendahl MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? *Nat Rev Gastroenterol Hepatol.* (2017) 14:9–21. doi: 10.1038/nrgastro.2016.169
10. Wang X, Hu WY, Song DG, Li Z, Du HH, Lu ZQ, et al. Porcine lactoferrin-derived peptide LFP-2 protects intestinal barrier by maintaining tight junction complex and modulating inflammatory response. *Biochem Pharmacol.* (2016) 104:74–82. doi: 10.1016/j.bcp.2016.01.009
11. Brogden KA, Ackermann M, McCray PB Jr, Tack BF. Antimicrobial peptides in animals and their role in host defences. *Int J Antimicrob Agents.* (2003) 22:465–78. doi: 10.1016/S0924-8579(03)00180-8
12. Tai EK, Wu WK, Wang XL, Wong HP, Yu L, Li ZL, et al. Intracellular administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnplt(-/-) mice. *Gene Ther.* (2013) 20:187–93. doi: 10.1038/gt.2012.22
13. Otte JM, Zdebik AE, Brand S, Chromik AM, Strauss S, Schmitz F, et al. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. *Regul Pept.* (2009) 156:104–17. doi: 10.1016/j.regpep.2009.03.009
14. Yi H, Hu W, Chen S, Lu Z, Wang Y. Cathelicidin-WA improves intestinal epithelial barrier function and enhances host defense against enterohemorrhagic *Escherichia coli* O157:H7 infection. *J Immunol.* (2017) 198:1696–705. doi: 10.4049/jimmunol.1601221
15. Arias-Barrau E, Dirusso CC, Black PN. Methods to monitor fatty acid transport proceeding through vectorial acylation. *Methods Mol Biol.* (2009) 580:233–49. doi: 10.1007/978-1-60761-325-1_13
16. Jang C, Oh SE, Wada S, Rowe GC, Liu L, Chan MC, et al. Branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. *Nat Med.* (2016) 22:421–6. doi: 10.1038/nm.4057
17. Chen M, Yang Y, Braunstein E, Georgeson KE, Harmon CM. Gut expression and regulation of FAT/CD36: possible role in fatty acid transport in rat enterocytes. *Am J Physiol Endocrinol Metab.* (2001) 281:E916–23. doi: 10.1152/ajpendo.201.281.5.E916
18. Ogawara N, Kojima T, Go M, Ohkuni T, Koizumi J, Kamekura R, et al. PPAR gamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells. *Pharmacol Res.* (2010) 61:489–98. doi: 10.1016/j.phrs.2010.03.002
19. Flores JJ, Klébe D, Rolland WB, Lekic T, Krafft PR, Zhang JH. PPARgamma-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats. *Neurobiol Dis.* (2016) 87:124–33. doi: 10.1016/j.nbd.2015.12.015
20. Hebert DN, Carruthers A. Glucose transporter oligomeric structure and function. *Trends Endocrin Met.* (2009) 20:72–7. doi: 10.1016/j.tem.2008.11.001
21. Su X, Abumrad NA. Cellulose fatty acid uptake: a pathway under construction. *Trends Endocrin Met.* (2009) 20:72–7. doi: 10.1016/j.tem.2008.11.001
22. Hamilton JA. New insights into the roles of proteins and lipids in membrane transport of fatty acids. *Prostag Leukotr Ess.* (2007) 77:355–61. doi: 10.1016/j.plefa.2007.10.020
23. Jay AG, Hamilton JA. The enigmatic membrane fatty acid transporter CD36: new insights into fatty acid binding and their effects on uptake of oxidized LDL. *Prostag Leukotr Ess.* (2018) 138:64–70. doi: 10.1016/j.plefa.2016.05.005
24. Abumrad N, Harmon C, Ibrahima A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. *J Lipid Res.* (1998) 39:2309–18.
25. McArthur MJ, Atshaves BP, Frolov A, Foxworth WD, Kier AB, Schroeder F. Cellular uptake and intracellular trafficking of long chain fatty acids. *J Lipid Res.* (1999) 40:1371–83.

26. Glatz JF, Luiken JJ, Bonen A. Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. *J Mol Neurosci.* (2001) 16:123–32; discussion 151–7. doi: 10.1385/JMN:16:2-3:123

27. Lobo S, Wiczer BM, Smith AJ, Hall AM, Bernlohr DA. Fatty acid metabolism in adipocytes: functional analysis of fatty acid transport proteins 1 and 4. *J Lipid Res.* (2007) 48:609–20. doi: 10.1194/jlr.M600441-JLR200

28. Trigatti BL, Anderson RGW, Gerber GE. Identification of caveolin-1 as a fatty acid binding protein. *Biochem Biophys Res Co.* (1999) 255:34–9. doi: 10.1006/bbrc.1998.0123

29. Yen CLE, Stone SJ, Koliwad S, Harris C, Farese RV. DGAT enzymes and triacylglycerol biosynthesis. *J Lipid Res.* (2008) 49:2283–301. doi: 10.1194/jlr.R800018-JLR200

30. Winer DA, Luck H, Tsai S, Winer S. The intestinal immune system in obesity and insulin resistance. *Cell Metab.* (2016) 23:413–26. doi: 10.1016/j.cmet.2016.01.003

31. Konig J, Wells J, Cani PD, Garcia-Rodenas CL, MacDonald T, Mercenier A, et al. Human intestinal barrier function in health and disease. *Clin Transl Gastroenterol.* (2016) 7:e196. doi: 10.1038/ctg.2016.54

32. Han F, Zhang H, Xia X, Xiong H, Song D, Zong X, et al. Porcine beta-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis. *J Immunol.* (2015) 194:1882–93. doi: 10.4049/jimmunol.1402300

33. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterol.* (2014) 14:189. doi: 10.1186/s12876-014-0189-7

34. Zhang H, Xia X, Han F, Jiang Q, Rong Y, Song D, et al. A novel antimicrobial peptide from bungarus fasciatus, attenuates disease in a dextran sulfate sodium model of colitis. *Mol Pharm.* (2015) 12:1648–61. doi: 10.1021/acs.molpharmaceut.5b00069

35. Akiyama T, Niyonsaba E, Kiatsurayanon C, Nguyen TT, Usghio H, Fujimura T, et al. The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function. *J Innate Immun.* (2014) 6:739–53. doi: 10.1159/000362789

36. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr Rev.* (1999) 20:649–88. doi: 10.1210/edrv.20.5.0380

37. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. *Nature.* (2008) 454:470–7. doi: 10.1038/nature07202

38. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. *Trends Immunol.* (2007) 28:551–8. doi: 10.1016/j.it.2007.09.003

39. Ponferrada, Caso JR, Alou L, Colon A, Sevillaño D, Moro MA, et al. The role of PPAR gamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. *Gastroenterology.* (2007) 132:1791–803. doi: 10.1053/j.gastro.2007.02.032

40. Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPAR alpha and PPAR gamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. *Faseb J.* (2009) 23:1596–606. doi: 10.1096/fj.08-121624

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Zong, Cao, Wang, Xiao, Wang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.